Endo Pharmaceuticals

Endo Pharmaceuticals
Share

Endo Pharmaceuticals

 •  March 4

Endo International plc (NASDAQ / TSX: ENDP) today announced that it has applied to the Toronto Stock Exchange (the "TSX") to have its ordinary shares delisted from the TSX at the close of business on March 17, 2017. This application is being made due to the limited trading volume of Endo's ordinary shares on the TSX (less than 1% of the trading in...

Endo Pharmaceuticals

 •  January 30

Endo International plc (NASDAQ / TSX: ENDP) announced today that one of its operating companies, Par Pharmaceutical has received final approval from the U.S. Food and Drug Administration for its New Drug Application for ephedrine sulfate injection, a drug administered parenterally as a pressor agent to address clinically important hypotension in...

Endo Pharmaceuticals

 •  December 6, 2016

Endo International plc (NASDAQ / TSX: ENDP) announced today that one of its operating companies, Par Pharmaceutical, has begun shipping mycophenolate mofetil hydrochloride (HCl) for injection following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par's mycophenolate mofetil hydrochloride (HCl)...

Endo Pharmaceuticals

 •  September 30, 2016

Study Participants in the Higher Dose Groups Treated with a Single Injection of XIAFLEX® Showed Statistically Significant Decrease in Size and Hardness of Dupuytren's Disease Nodules, a Pre-Cursor Condition to Dupuytren's Contracture
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), today announced new...

Endo Pharmaceuticals

 •  June 28, 2016

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that one of its operating companies, Par Pharmaceutical, has been issued a new patent by the U.S. Patent and Trademark Office (PTO) relating to Vasostrict® (vasopressin injection, USP) 20 units/mL. The PTO has issued to Par U.S. Patent No. 9,375,478, which has an expiration date of...

Endo Pharmaceuticals

 •  March 21, 2016

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today provided a statement and a Frequently Asked Questions (FAQs) document regarding the expected approval by the U.S. Food and Drug Administration of a competitor's generic version of Voltaren® Gel (diclofenac sodium topical gel) 1%.
Endo is evaluating a number of options regarding Voltaren® Gel...

Endo Pharmaceuticals

 •  March 10, 2016

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that Rajiv De Silva, President and CEO, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 in Miami at 1:05 p.m. ET.
A live webcast and audio archive for the event will be available on the Company's website at www.endo.com....

Endo Pharmaceuticals

 •  March 9, 2016

- New educational campaign puts a spotlight on a lesser-known men's health condition that can affect as many as one in 10 men worldwide
- Dr. Punch encourages affected men to visit www.AskAboutTheCurve.com to learn more and to step up and face their challenge head on
Nationally-recognized and long-standing sports announcer Jerry Punch, M.D., is...

Endo Pharmaceuticals

 •  February 22, 2016

New opioid analgesic with novel drug delivery now available by prescription in U.S.
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), today announced the availability of BELBUCA™ (buprenorphine) buccal film, the first and only buprenorphine formulation developed with a dissolving film that is absorbed...

Endo Pharmaceuticals

 •  February 17, 2016

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced the initiation of its Phase 2b study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known as cellulite. CCH is known in its currently approved indications in the U.S. as XIAFLEX®.
"Cellulite affects...